Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Nephrol. Dec 25, 2024; 13(4): 98709
Published online Dec 25, 2024. doi: 10.5527/wjn.v13.i4.98709
Published online Dec 25, 2024. doi: 10.5527/wjn.v13.i4.98709
What is new in the pathogenesis and treatment of IgA glomerulonephritis
Maurizio Salvadori, Department of Renal Transplantation, Careggi University Hospital, Florence 50139, Tuscany, Italy
Giuseppina Rosso, Division of Nephrology, San Giovanni di Dio Hospital, Florence 50143, Toscana, Italy
Co-first authors: Maurizio Salvadori and Giuseppina Rosso.
Author contributions: Salvadori M and Rosso G equally contributed to generating the manuscript. Both authors wrote, controlled and approved the final version of the manuscript
Conflict-of-interest statement: Maurizio Salvadori and Giuseppina Rosso do not have any conflict of interest in relation to the manuscript, as in the attached form.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Maurizio Salvadori, MD, Professor, Department of Renal Trans
Received: July 3, 2024
Revised: September 29, 2024
Accepted: October 8, 2024
Published online: December 25, 2024
Processing time: 126 Days and 19.5 Hours
Revised: September 29, 2024
Accepted: October 8, 2024
Published online: December 25, 2024
Processing time: 126 Days and 19.5 Hours
Core Tip
Core Tip: Genetic wide association studies (GWAS) and studies on microbiota allowed finding new aspects in pathogenesis of IgA nephropathy. GWAS allowed finding new genes related to the different IgA nephropathy phases. Microbiota allowed finding new roles exerted by microbes in mucosa immune system and in IgA pathogenesis. Treatment of chronic kidney disease must be always associated to the immune treatment. In the latter fundamental role is exerted by steroids. Recent studies found the relevance of anti B cell-activating factor and anti A proliferation-inducing ligand agents even if the majority of these studies are still in phases II/III. Similarly in premarketing studies are the anti-complement agents.